PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALL

This phase 3 trial gives oncology pharmacists the first randomized comparison of a sequential ponatinib-blinatumomab regimen against imatinib plus chemotherapy, with detail on dosing, toxicity, and monitoring.
📅 Journal publication: Oct 15, 2026 · Last updated: Oct 15, 2026
★ Editor's Pickponatinibblinatumomabimatinibtyrosine kinase inhibitorbispecific T-cell engagerPhiladelphia chromosome-positive acute lymphoblastic leukemiaphase 3 randomized trialchemotherapy-freemeasurable residual diseaseGIMEMA ALL2820oncology pharmacy Oncology Pharmacy

Background Information

Chemotherapy-free regimen improves survival in Ph-positive ALL.

This study evaluates a novel chemotherapy-free approach in treating Philadelphia-positive acute lymphoblastic leukemia (ALL), potentially improving outcomes. 24-month event-free survival was 86% with ponatinib plus blinatumomab, versus 67% with imatinib plus chemotherapy (P<0.001). This phase 3 trial suggests a superior, less toxic treatment option for Ph-positive ALL, but further validation is needed for widespread adoption. Ponatinib with blinatumomab outperforms imatinib plus chemotherapy in treating Ph-positive ALL.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Chiaretti S, Piciocchi A, Skert C, Leoncin M, Borlenghi E, Cattaneo C, Di Trani M, Elia L, Almici G, Cardinali D, Kaiser F, Lussana F, Fiumara PF, Maugeri C, Alati C, Martino M, Ansuinelli M, Lucco Navei G, Mattei D, Soddu S, Messina M, Marino MR, Mancini V, Chiusolo P, Scappini B, Martelli MP, Salutari P, Cerrano M, Serio B, Cucca A, Luppi M, Pochintesta L, Pasciolla C, Romani C, Mosna F, Bonifacio M, Tanasi I, Fracchiolla NS, Bocchia M, Imbergamo S, Califano C, Nunziata GR, Annunziata M, Mulé A, Zappasodi P, Mastaglio S, Butera S, Della Porta MG, Porretto F, Lunghi M, De Bellis E, Todisco E, Basilico CM, Fazi P, Rambaldi A, Bassan R, Foà R, GIMEMA Investigators

Citation: Chiaretti S, Piciocchi A, Skert C, et al. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. The New England journal of medicine. 2026;395(15):1483-1494. doi:10.1056/NEJMoa2606208

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →